Curcumin is a potent anti-cancer drug in several types of human cancers. Despite of several preclinical and clinical studies of curcumin, the precise mechanism of curcumin in cancer prevention has remained unclear. In our study, we for the first time investigated whole transcriptome alteration in A549 non-small cell lung cancer (NSCLC) cell lines after treatment with curcumin using RNA sequencing. We found that lots of genes and signaling pathways were significantly altered after curcumin treatment in A549 cells. With bioinformatics approaches (gene ontology, Kyoto Encyclopedia of Genes and Genomes, and STRING), we found that those curcumin altered genes were not only the genes that induce cell death but also those extracellular matrix receptors and mitogen-activated protein kinase signaling pathway genes which regulate cell migration and proliferation. Among those significantly altered genes, eight genes (COL1A1, COL4A1, COL5A1, LAMA5, ITGA3, ITGA2B, DDIT3, and DUSP1) were further examined by quantitative reverse transcription polymerase chain reaction and western blot analysis in four non-small cell lung cancer cell lines. Both in cell lines and in mouse model, the extracellular matrix receptors including the integrin (ITGA3 and ITGA2B), collagen (COL5A1), and laminin (LAMA5) were significantly inhibited by curcumin at messenger RNA and protein levels. Functional studies confirmed that curcumin not only induced A549 cell death but also repressed cell proliferation and migration by regulating extracellular matrix receptors. Collectively, our study suggests that curcumin may be used as a promising drug candidate for intervening lung cancer in future studies.
Introduction
Curcumin is the main bioactive component of Indian spice turmeric which is widely used in Indian and Chinese medicines for centuries. 1 Curcumin possesses various therapeutic roles including anti-cancer, anti-microbial, anti-oxidant, and anti-inflammatory activities. 1 Curcumin can attenuate cancer cell proliferation and induce cell apoptosis by regulating multiple signaling pathways such as p53, Ras, PI3K, AKT, Wnt/β-catenin, and mTOR (mechanistic target of rapamycin). 2 Curcumin can also inhibit cancer cell migration, invasion, and metastasis by altering the expression of adhesion molecules, inflammatory factors, growth factors, and growth factor receptors. [3] [4] [5] [6] [7] Some clinical trials confirm that curcumin is a potent anti-cancer drug with safety and minimal toxicity in patients. 8 Lung cancer is one of the deadliest cancers with high morbidity and mortality in the world. 9 Although new chemotherapeutic drugs and treatment approaches have been developed in lung cancer treatment, the prognosis of patients remains poor. 10 During the past decades, several studies demonstrated that curcumin, as a naturally occurring polyphenol compound, showed promising in vitro and in vivo anti-cancer activity in lung cancer. 11 Curcumin suppressed lung cancer cell growth and induced cell death through inducing autophagy and inhibiting Bcl-2, cyclin D1, cyclin-dependent kinase 2 (CDK2), and CDK4. 12, 13 By downregulating epidermal growth factor receptor (EGFR) expression, curcumin can block EGFR downstream tyrosine kinase signaling cascade and overcome acquired EGFR-tyrosine kinase inhibitors (TKIs) resistance. [14] [15] [16] By inhibiting Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway, curcumin attenuated the stem-like traits of lung cancer cells and enhanced the anti-tumor effects of cisplatin. 17, 18 But, until now, there have never been studies investigating the effects of curcumin on lung cancer cells at whole transcriptome level. Herein, we used RNA sequencing (RNA-seq; a well-developed tool to analyze the eukaryotic transcriptome) to gain a global view of curcumin-induced whole transcriptome alteration in human non-small cell lung cancer (NSCLC) cell line A549. After a systemic analysis of curcumin-induced whole transcriptome alteration, our study provided precise molecular targets and signaling pathways that curcumin regulated, which contributes to better application of curcumin in lung cancer treatment.
Materials and methods

Reagents and cell culture
Antibody against ITGA3 was purchased from Millipore (AB1920; Billerica, MA, USA). Antibody against LAMA5 was purchased from Biorbyt (orb214177; San Francisco, CA, USA). COL5A1 antibody was obtained from Santa Cruz Biotechnology (sc-133162; CA, USA). ITGA2B antibody was obtained from Abcam (ab134131; Cambridge, UK). Ki67 (#9449) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; #2118) antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Protein concentration was determined with bicinchoninic acid (BCA) kit that was purchased from Thermo Fisher scientific (Waltham, MA, USA). Curcumin was obtained from Selleck Chemicals (S1848; Houston, TX, USA) and dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) to make stock solution.
Human NSCLC cell lines A549, H1299, H460, and PC9 were obtained from American Type Culture Collection and cultured in RPMI-1640 medium (Gibco, Life Technologies, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum (FBS) at 37°C in 5% CO 2 /95% air.
RNA-seq library preparation and sequencing
Total RNA was isolated from 4 × 10 6 A549 cells treated with or without curcumin using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The integrity of total RNA was assessed using an Agilent 2100 Bioanalyzer (Life Technologies, Carlsbad, CA, USA) with a RNA integrity number (RIN) greater than 8. After two rounds of purification using poly-T oligo-attached magnetic beads, the messenger RNA (mRNA) was purified from total RNA (2 µg) and fragmented. Cleaved RNA fragments were primed with random hexamers and then reverse transcribed into first-strand complementary DNA (cDNA) using reverse transcriptase and random primers. The RNA template was removed and a replacement strand was synthesized to generate double-stranded cDNA. End repair, A-tailing, adaptor ligation, cDNA template purification, and enrichment of the purified cDNA templates were then performed using polymerase chain reaction (PCR). Constructed libraries were 100 bp paired-ends and sequenced by Illumina Hiseq2000 sequencer (Suzhou Zhongxin Biotechnology Co., Ltd, Suzhou, China). The RNA-seq data in our study had been submitted to Sequence Read Archive (SRA) database, with SRA number SRP065304.
RNA sequencing data alignment
We aligned the sequencing reads to a human genome reference (hg19) using TopHat version 2.0.13. Splice junctions were extracted from RefSeq alignment (downloaded from the University of California, Santa Cruz (UCSC) Genome Browser). The resulting read alignments were assembled through Cufflinks version 1.1, and it created a novel transcript using Cufflinks reference annotation-based transcript (RABT) algorithm. The transcripts combined with Cuffcompare were used to calculate relative abundances of each transcript through Cuffdiff. Gene expression levels were determined by measuring the sum of fragments per kilobase of exon model per million mapped reads (FPKM) values of its exons. The RNA-seq data were imported into R for Volcano plot using statistical test (two-factor analysis of variance (ANOVA)) with an adjusted p value of 0.05 for significance.
RNA extraction and real-time PCR
Total RNA was extracted from cancer cells using the TRIzol Reagent (Invitrogen, Life technologies, Carlsbad, CA, USA) following the manufacturer's instructions.
Reverse transcription was performed with Fermentas K1622 (Thermo Fisher scientific, Waltham, MA, USA) following the manufacturer's instructions. Quantitative reverse transcription PCR (qRT-PCR) was conducted using SYBR Green (ABgene, Epsom, UK) according to the manufacturer's instructions. Primer sequences were listed in Supplementary Table S1 .
Cell Counting Kit-8 assay
The cell viability after curcumin treatment was determined with Cell Counting Kit-8 (CCK8) assay. Briefly, 3000 cells per well were seeded onto 96-well plate and incubated overnight. Then, the cells were treated with different concentrations of curcumin. After incubation for 48 h, the medium in each well was replaced with fresh culture medium containing 10 µL CCK8 (Dojindo Molecular Technologies, Kumamoto, Japan). The plates were incubated for additional 3 h, and then, the absorbance was determined at 450 nm with a microplate spectrophotometer (SpectraMAX M2e; Molecular Devices, Silicon Valley, CA, USA).
Colony formation assay
Cells were seeded onto six-well plates. After adherent growth, the cells were treated with 8 µg/mL curcumin or 0.1% DMSO as a control and incubated for 9 days. After washing with phosphate-buffered saline (PBS), the cells were fixed with methanol for 10 min at room temperature, and then, the crystal violet solution (C0121; Beyotime, Shanghai, China) was added onto the plates and incubated for 30 min at 37°C. Then, the plates were washed with deionized water and dried at room temperature. The colonies in each plate were counted by two experienced researchers.
Wound healing assay
Cells were seeded onto six-well plates and cultured to adherent growth. The adherent monolayer cells were scratched with a sterile 10 µL pipette tip to create a narrow wound-like gap. After washing twice with sterile PBS to remove loose cells and cell debris, the medium was replaced with fresh FBS-free medium containing 8 µg/mL curcumin or 0.1% DMSO (v/v) as a control. After 48 h, the wounds were photographed under the microscope.
Flow cytometry analysis
After treatment with 8 µg/mL curcumin for 24 or 48 h, A549 cells were harvested, washed with ice-cold PBS, and re-suspended in binding buffer. Cells treated with 0.1% DMSO (v/v) were used as a control. Cell suspension was stained with Alexa Fluor 488-conjugated annexin V (AV) and propidium iodide (PI) at room temperature in the dark. After incubation for 5 min, cells were analyzed by FC500 flow cytometer (Beckman-Coulter, CA, USA). The CXP CellQuest software (Beckman-Coulter) was used to count the number of apoptotic (Alexa Fluor 488+/PI− and Alexa Fluor 488+/PI+) and necrotic (Alexa Fluor 488−/PI+) cells.
Western blot analysis
Cells were harvested after indicated treatments and washed twice with ice-cold PBS before adding into protein extraction buffer. Equal amount of proteins was fractionated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% non-fat milk, PVDF membrane was incubated with diluted primary antibodies (GAPDH: 1:5000 dilution, Ki67: 1:5000 dilution, LAMA5: 1:1000 dilution, COL5A1: 1:1000 dilution, ITGA2B: 1:1000 dilution, and ITGA3: 1:1000 dilution) at 4°C overnight. Then, the membrane was washed with Tris buffered saline with Tween 20 (TBST) three times at room temperature and incubated with corresponding horseradish peroxidase (HRP)-linked secondary antibody for 2 h at room temperature. Proteins were ultimately visualized by enhanced chemiluminescence and autoradiography (Thermo Fisher Scientific, Waltham, MA, USA).
Xenograft transplantation and therapy
Four-week-old BALB/c nude mice were purchased from SLAC laboratory Animal Co., Ltd (Shanghai, China) and maintained under standard conditions in Experimental Animal Center in Zhejiang Chinese Medicine University (Zhejiang, China). All the animal protocols in our study were in accordance with the institutional animal welfare guidelines of Zhejiang Chinese Medicine University. To develop xenograft tumors, in vitro growing A549 cells were harvested by exposing to trypsin-ethylenediaminetetraacetic acid (EDTA) and washed with ice-cold PBS. A volume of 5 × 10 6 A549 cells in 100 µL PBS were implanted into the right flanks of BALB/c nude mice. Two weeks later, tumor-bearing mice were intraperitoneally administrated with 0.1% DMSO or 150 mg/kg curcumin daily for three consecutive days. After 10 days, all mice were sacrificed according to institutional guidelines, and tumors were resected for protein extraction. Tumor volume (mm 3 ) was calculated using the following formula: V (mm 3 ) = A (mm) × B (mm 2 ) / 2, where A and B were the longest and widest diameter of tumor, respectively, and measured for every 2 days by a caliper.
Database for Annotation, Visualization and Integrated Discovery analysis
Database for Annotation, Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov), Functional Annotation Bioinformatics Microarray Analysis was used to identify significantly enriched gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms among the given list of genes that are differentially expressed in response to curcumin. Statistically overrepresented GO and KEGG categories with p ≤ 0.01 were considered significant.
Statistical analysis
Statistical data were represented as mean ± standard deviation from at least three independent experiments performed in triplicate. The colony formation, gene expression, and tumor volume were statistically analyzed using repeated measures two-way ANOVA.
Results
Identification of curcumin-induced transcriptome alteration in A549 cells through RNA-seq analysis
In order to determine experimental conditions for transcriptome analysis, we performed the cytotoxicity assay of curcumin with A549 cancer cells. As shown in Supplementary Figure S1 , curcumin inhibited the viability of A549 cells in a dose-dependent manner. Among the tested doses, we found that the dosage of 8 µg/mL curcumin which induced 44.7% cell viability was the closest to the half maximal inhibitory concentration (IC 50 ) of curcumin after incubation for 48 h in A549 cells (Supplementary Figure S1) . So, the transcriptome analysis was performed on A549 cells after treatment with 8 µg/ mL curcumin for 48 h. The schematic diagram of our study was presented in Figure 1 (a). We acquired valid RNA-seq data from curcumin-treated (2,728,030 bp) and non-treated (2,902,959 bp) A549 cells with Q30 > 90%, respectively ( Supplementary Table S2 ). We filtered out our data with estimated FPKM values less than 1.0 in samples for more accurate results. Ultimately, with statistical analysis (Volcano plot), we found that the transcriptome of curcumin-treated A549 cells were significantly different from those of untreated cells (Figure 1(b) ). Totally 1993 differentially expressed genes (DEG) were identified in curcumin-treated A549 cells compared with untreated A549 cells. Among these genes, 1028 genes were upregulated at least two-fold and 965 genes were downregulated at least two-fold ( Supplementary Table  S3 ). The heatmap for some significantly altered genes by curcumin was shown in Figure 1 (c). According to cellular functional categorization, significantly upregulated genes were classified as follows (p ≤ 0.01): Steroid metabolic process (CYP3A5, AKR1C4, CYP1A1, INSIG2, SULT1A1, PCSK9, NR5A2, SCP2, AKR1C1, and DHCR24), negative regulation of cell proliferation (HYAL1, CTTNBP2, CDC6, RBP4, CTH, ANG, GDF11, AXIN2, GPNMB, FOXO4, BMP7, and DHCR24), cell motion (PLAT, VAV3, S100P, KIF5C, PF4, SCYL3, ITGAM, EPHA4, CTTNBP2, DOCK2, SAA2, ANK3, ANG, and BMP7), and cell migration (PLAT, CTTNBP2, DOCK2, S100P, VAV3, SAA2, ANG, PF4, SCYL3, and ITGAM). The significantly downregulated genes were classified as follows (p ≤ 0.01): response to virus (IFIH1, ZC3HAV1, RSAD2, CCL5,  APOBEC3F, IFI35, ISG20, ISG15, CXCR4, BCL2, MX1,  MX2, FOSL1, IL6, BST2, IFI44, IFI16, STAT1, TRIM22,  DDX58, IRF9, PLSCR1, IFNB1, LYST, and IRF7) , positive regulation of developmental process (TNFRSF12A, CSF1, FST, BTC, TGFB3, OXTR, TNFSF12, CCL5, GLI2, CDH4, SHH, EPHB2, TGFB2, LIF, METRN, BDNF, CYP27B1, GATA6, BCL2, HLX, GATA4, JUND, RHOB, RARA, IL2RG, HSF4, RUNX2, INSR, ARHGDIA, IL6, TESC, SOCS3, SPHK1, SMAD1, IL6R, NTRK3, CD83, SERPINF1, ETS1, JUN, JAK2, BMPR1B, and IGFBP3), and regulation of cell migration (PDGFB, CSF1, EDN1, TPM1, SHH, CITED2, TGFB2, CXCL10, NISCH, CXCR4, BCL2, INSR, COL18A1, ICAM1, IL6, IRS2, PTPRM, EGFL7, SPHK1, SCAI, IL6R, IRS1, LAMA5, CXCL16, PTP4A1, JAK2, MUC5AC, and IGFBP3) ( Supplementary  Table S3 ).
Identification of curcumin regulated signaling pathways in A549 cells through DAVID and STRING analysis
After bioinformatics analysis of RNA-seq data, the upregulated or downregulated genes in curcumin-treated A549 cells were summarized. Furthermore, we submitted these genes to DAVID (a web-based high-throughput functional genomics analysis tool) for systematically clustering these genes. In GOTERM_BP_FAT category, we identified significantly enriched GO terms and characterized curcumin-induced responses of A549 cells. In total, 4 subcategories (p ≤ 0.01) were found among upregulated genes and 66 subcategories (p ≤ 0.01) among downregulated genes ( Supplementary Table S4 ). In KEGG_PATHWAY category, the upregulated genes were clustered into only 2 subcategories (p ≤ 0.05) and downregulated genes were clustered into 11 subcategories (p ≤ 0.05, 6 subcategories with p ≤ 0.01) ( Supplementary  Table S5 ).
Based on transcriptome analysis, we found that curcumin mainly induced downregulation but not upregulation of target genes in A549 cells. The following signaling pathways were significantly altered in A549 cells after treatment with curcumin: small cell lung cancer, pathways in cancer, systemic lupus erythematosus, mitogenactivated protein kinase (MAPK) signaling pathway, extracellular matrix (ECM)-receptor interaction, and cytokine-cytokine-receptor interaction (Figure 1(d) ).
These results with bioinformatics analysis were matched with cellular functions of curcumin in A549 cells that include the induction of cell death and the repression of cell proliferation (signaling pathways: small cell lung cancer, pathways in cancer, and MAPK signaling pathway). The ECM-receptor interaction pathway was repressed after curcumin treatment, suggesting that curcumin may also repress A549 cell migration. Then, we performed STRING analysis of all downregulated ECMreceptor genes and found that COL1A1, COL4A1, COL5A1, LAMA5, ITGA3, ITGA2B, and DDIT3 were in the same protein-protein interaction network, suggesting that curcumin may repress cancer cell migration through downregulation of massive ECM-receptor genes (Figure 1(e) ).
Real-time RT-PCR validation of RNA-seq results
Through GO and KEGG analysis, we found that curcumin may not only induce cancer cell death but also affect cancer cell migration and proliferation through downregulating ECM receptors and MAPK-related genes. To validate the accuracy of RNA-seq results, 10 potential target genes of curcumin (COL1A1, COL4A1, COL5A1, LAMA5, ITGA3, ITGA2B, DDIT3, DUSP1, JUN, and MAPK11) were selected and analyzed by qRT-PCR. We found that the changes in these genes at mRNA levels by qRT-PCR were consistent with the RNA-seq results (Figure 2(a) and (b) ). In addition, these results suggested that our RNA-seq data were highly reliable and can be used to investigate the biological effects of curcumin on NSCLC cell lines.
Cellular functions of curcumin in A549 cancer cells
Since the RNA-seq analysis revealed that curcumin may not only cause cell death but also repress cell migration and proliferation. We analyzed curcumin-induced cell death by fluorescence-activated cell sorting (FACS) analysis ( Figure  3(a) ), cell proliferation by colony formation assay and western blot analysis (Figure 3(b) and (c)), and cell migration by wound healing assay (Figure 3(d) ). Compared with DMSO-treated group, curcumin caused massive A549 cell death (24.1% plus 6.3%) at a concentration of 8 µg/mL for 24 h which further increased (48.2% plus 1.5%) after 48 h incubation (Figure 3(a) ). Furthermore, curcumin significantly repressed colony formation of A549 cells ( Figure  3(b) ) and the protein level of a proliferation marker Ki67 (Figure 3(c) ). Wound healing assay was performed to investigate the inhibitory effects of curcumin on A549 cell migration. After 48 h treatment, we found that compared with DMSO-treated A549 cells, the migration of curcumintreated A549 cells were significantly repressed ( Figure  3(d) ). Based on the RNA-seq analysis, we suggest that the downregulation of ECM receptors by curcumin may play a critical role in the repression of A549 cell death, proliferation, and migration.
ECM receptors were significantly downregulated by curcumin in vitro and in vivo
When treated with curcumin at a concentration of 8 µg/mL (A549, H1299, and H460) or 4 µg/mL (PC9), the expression of ECM receptors was significantly repressed (Figure  4(a)-(d) ). Furthermore, western blot analysis was performed on the extractions of A549, H1299, H460, and PC9 cells treated with or without 8 µg/mL or 4 µg/mL curcumin for 48 h. Consistent with the RNA-seq and qRT-PCR results, the ECM receptors including ITGA3, COL5A1, and LAMA5 were obviously inhibited at protein level after treatment with curcumin (Figure 4(e) ). In xenograft tumors, curcumin significantly reduced tumor size ( Figure  5(a) and (b) ). In addition, the expression levels of ECM receptors (ITGA3, ITGA2B, COL5A1, and LAMA5) were detected in tumor samples with or without curcumin treatment. As shown in Figure 5 (c), we found that the expression of these proteins was repressed in all curcumin-treated tumors. Therefore, our study suggests that downregulation of ECM receptors by curcumin may be one of the major causal factors for A549 cell death and the repression of cell proliferation and migration.
ECM receptors were highly expressed in human cancers with ONCOMINE analysis
Since the expression of ECM receptors was significantly inhibited by curcumin, our study investigated whether ECM receptors were highly expressed in human cancer tissues. The expression levels of ECM receptors, including integrin (ITGA3 and ITGA2B), collagen (COL1A1, COL4A1, and COL5A1), and laminin (LAMA5), were examined by ONCOMINE. Compared with human normal tissues, ECM receptors except for ITGA2B were significantly highly expressed in human cancer tissues ( Figure 6(a) ). In lung cancer, we found that the collagens (COL1A1 and COL5A1) were significantly upregulated either in lung adenocarcinoma or in squamous cell lung carcinoma ( Figure 6(b) ). Therefore, curcumin, as a potent inhibitor of ECM receptors, can be used for treating human cancers with highly expressed ECM receptors.
Discussion
This study investigated curcumin-regulated molecular targets and signaling pathways at whole transcriptome level by RNA-seq in A549 NSCLC cell lines. Many signaling pathways were altered in curcumin-treated A549 cells, including cell apoptosis. This is consistent with previous studies which showed that curcumin induces cancer cell apoptosis via multiple targets such as Notch signaling, nuclear factor kappa B (NF-κB) pathway, and PI3K/AKT signaling pathway. [19] [20] [21] [22] [23] [24] [25] Our RNA-seq data reveals that curcumin has significant inhibitory effects on the expression of ECM receptors, including collagen (COL1A1, COL4A1, and COL5A1), integrin (ITGA2B and ITGA3), and laminin (LAMA5) in A549 cells. This result was also confirmed in other NSCLC cell lines and xenograft tumor models. Curcumin downregulates the expression of ECM receptors at both the RNA and protein levels. So we suggest that by regulating the ECM-receptor interaction pathway, curcumin inhibited cell proliferation and invasion and induced death in A549 cancer cells.
The ECM receptors are transmembrane proteins that are required for cell-cell binding or cell binding to extracellular molecules. 26 The aberrant activation of the ECMreceptor interaction pathway is involved in cell survival, proliferation, migration, polarity, and differentiation. [27] [28] [29] The adhesion of cancer cells to ECM via collagen and integrin induced the activation of various pro-survival pathways such as PI3K/Akt, p53/MAPK, extracellular signal-regulated kinase (ERK)/MAPK, and Rho/ROCK conferring resistance to chemotherapeutic agents. [30] [31] [32] [33] In vivo studies show that high expression of ECM receptors is closely associated with a poor prognosis of patients through increasing chemoresistance and metastatic potential. 34 Collagen XVII and laminin-5 are linked to the activation of epithelial-mesenchymal transition (EMT) and poor prognosis in lung cancer patients. 35 In NSCLC, integrin regulated cancer cell invasion, metastasis, and chemoresistance. [36] [37] [38] [39] [40] Integrin inhibitors have been developed to reverse malignant phenotype of human cancers. Some of the inhibitors have entered into clinical trials, which can significantly improve cancer patients' survival rate. 41, 42 Volociximab, an α5β1 inhibiting antibody, in combination with carboplatin and paclitaxel, has completed a phase II study, for advanced NSCLC. 43 Kumar et al. 44 found that curcumin inhibited tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppressing cell surface expression of adhesion molecules and of nuclear factor-κB activation. Herein, our findings show that ECM receptors including collagen, integrin, and laminin are the main therapeutic targets of curcumin, and curcumin can be used as another promising drug candidate to intervene in NSCLC.
In addition to lung cancer, our bioinformatics analysis revealed that ECM receptors including collagen (COL1A1, COL4A1, and COL5A1), integrin (ITGA2B and ITGA3), and laminin (LAMA5) are also highly expressed in many other human cancers, such as colorectal cancer, esophagus cancer, gastric cancer, and head and neck cancer. In these cancers, curcumin may also have potent anti-tumor activities by regulating the expression of ECM receptors. Our study discovered ECM receptors as the main targets of curcumin by RNA-seq in A549 cells, which suggests that curcumin may be used alone or in combination with other anti-cancer drugs to reverse ECM-receptors-associated malignant phenotype of human cancers. However, there are some limitations with our current study. Statistical analyses were not performed for some experiments including wound healing assay and cell death assays. The inhibitory effects of curcumin on lung cancer metastasis should be investigated in vivo by the establishment of a metastasis xenograft tumor model. To further ensure the efficacy of curcumin in lung cancer, more studies are needed including the assessment of safety, side effects, and pharmacokinetics of curcumin by in vivo studies. Furthermore, the precise mechanisms by which curcumin downregulates the expression of ECM receptors should be discovered. 
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